Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancerSanteon SCLC Study Grp, Cramer-van der Welle, C. M., Schramel, F. M. N. H., van Leeuwen, A. S., Groen, H. J. M. & van de Garde, E. M. W., 14-May-2020, In : European journal of cancer care. p. e13250 6 p., 13250.
Research output: Contribution to journal › Article › Academic › peer-review
Objective Clinical outcome data on patients with extensive disease small cell lung cancer (ED SCLC) treated in routine practice is limited. The aim of this retrospective study is to present data on treatment patterns and survival in an unselected patient population with ED SCLC.
Methods All patients diagnosed with ED SCLC between 2008 and 2014 in six Dutch large teaching hospitals (Santeon network) were included. We collected data on patient characteristics, systemic treatments, overall survival (OS), dose reductions (
Results From 792 diagnosed patients, 568 (72%) started with first-line treatment. Of these patients, 41% received second-line treatment. Only 68 patients received third-line treatment. For all treated patients, the mean age was 66 years. The majority (72%) had a performance status (ECOG) of 0 or 1 at diagnosis. Median OS of treated patients was 7.4 months. Of all patients with first-line treatment, 26% received
Conclusion After first-line systemic treatment in ED SCLC the fraction of patients receiving subsequent lines of treatment is rapidly decreasing. This information is necessary as background for evaluation of the added value of future drugs under study for ED SCLC.
|Number of pages||6|
|Journal||European journal of cancer care|
|Early online date||2020|
|Publication status||Published - 14-May-2020|
- effectiveness, pharmacotherapy, real-world, small cell lung cancer, survival, treatment patterns, NETHERLANDS, SURVIVAL, PROGRESS